Reviva Pharmaceuticals Holdings, Inc.
brilaroxazine
schizophrenia
Countdown
267days
Phase 3 readout · ~ Mar 31, 2027 estimated
What's at stake
Phase 3 trial results for brilaroxazine in schizophrenia are due ~ Mar 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“the Company currently expects study completion in Q4 2027.”